Stock BIOCON BIOCON LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biocon Limited

Equities

BIOCON

INE376G01013

Biotechnology & Medical Research

Market Closed - NSE India S.E.
Other stock markets
 07:43:47 2024-04-26 am EDT 		5-day change 1st Jan Change
306.4 INR +5.06% Intraday chart for Biocon Limited +17.10% +22.73%
Apr. 18 India's Biocon developing its own version of Wegovy, clinical trial likely next year RE
Apr. 18 Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil MT

Valuation

Fiscal Period: Maart 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 360,832 320,015 484,623 399,173 246,192 365,838 - -
Enterprise Value (EV) 1 356,129 329,826 481,237 420,987 399,898 505,058 508,785 502,136
P/E ratio 40.2 x 42.9 x 66.1 x 61.9 x 53.3 x 38.5 x 42.9 x 25.4 x
Yield 0.16% 0.18% - 0.15% 0.73% 0.43% 0.47% 0.64%
Capitalization / Revenue 6.54 x 5.03 x 6.82 x 4.88 x 2.2 x 2.52 x 2.21 x 1.88 x
EV / Revenue 6.46 x 5.18 x 6.77 x 5.14 x 3.58 x 3.48 x 3.07 x 2.57 x
EV / EBITDA 25.6 x 20.6 x 29.2 x 21.4 x 17.1 x 16.7 x 13.4 x 10.7 x
EV / FCF -528 x -103 x -135 x -80.8 x 156 x 32 x 36.5 x 28.7 x
FCF Yield -0.19% -0.97% -0.74% -1.24% 0.64% 3.12% 2.74% 3.48%
Price to Book 6.01 x 4.84 x 6.37 x 4.76 x 1.39 x 1.91 x 1.82 x 1.68 x
Nbr of stocks (in thousands) 1,181,990 1,182,830 1,185,188 1,189,431 1,193,080 1,193,988 - -
Reference price 2 305.3 270.6 408.9 335.6 206.4 306.4 306.4 306.4
Announcement Date 4/25/19 5/14/20 4/28/21 4/28/22 5/23/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Maart 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 55,144 63,672 71,058 81,840 111,742 145,005 165,808 195,031
EBITDA 1 13,937 16,031 16,506 19,702 23,447 30,198 37,940 46,733
EBIT 1 9,459 10,509 9,355 11,560 12,316 14,711 22,262 30,755
Operating Margin 17.15% 16.5% 13.17% 14.13% 11.02% 10.15% 13.43% 15.77%
Earnings before Tax (EBT) 1 12,149 11,860 10,774 9,831 8,971 13,493 15,353 23,596
Net income 1 9,053 7,482 7,405 6,484 4,627 9,492 9,296 14,089
Net margin 16.42% 11.75% 10.42% 7.92% 4.14% 6.55% 5.61% 7.22%
EPS 2 7.600 6.300 6.190 5.420 3.870 7.961 7.143 12.07
Free Cash Flow 1 -675 -3,211 -3,572 -5,212 2,565 15,765 13,943 17,481
FCF margin -1.22% -5.04% -5.03% -6.37% 2.3% 10.87% 8.41% 8.96%
FCF Conversion (EBITDA) - - - - 10.94% 52.21% 36.75% 37.41%
FCF Conversion (Net income) - - - - 55.44% 166.09% 149.99% 124.07%
Dividend per Share 2 0.5000 0.5000 - 0.5000 1.500 1.322 1.428 1.946
Announcement Date 4/25/19 5/14/20 4/28/21 4/28/22 5/23/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: Maart 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 18,510 18,387 17,606 18,404 21,742 24,088 21,395 23,197 29,411 37,739 34,226 36,196 36,732 38,945 37,706
EBITDA 1 3,995 4,358 3,893 4,458 4,882 5,919 3,994 4,707 6,443 9,572 7,144 8,475 8,373 8,219 -
EBIT 1 2,132 2,515 1,945 2,443 2,825 3,797 1,819 2,399 3,432 5,935 3,564 4,572 4,553 4,102 3,351
Operating Margin 11.52% 13.68% 11.05% 13.27% 12.99% 15.76% 8.5% 10.34% 11.67% 15.73% 10.41% 12.63% 12.4% 10.53% 8.89%
Earnings before Tax (EBT) 1 2,363 3,661 1,657 2,060 2,689 3,425 1,969 2,291 -255 4,966 1,837 2,676 2,930 2,319 -
Net income 1 1,686 2,532 844 1,383 1,871 2,386 1,444 470 -418 3,132 1,014 1,652 1,808 2,164 -
Net margin 9.11% 13.77% 4.79% 7.51% 8.61% 9.91% 6.75% 2.03% -1.42% 8.3% 2.96% 4.56% 4.92% 5.56% -
EPS 2 1.400 2.120 0.7100 1.160 1.560 1.990 1.210 0.3900 -0.3500 2.620 0.8500 1.460 1.620 1.150 -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 1/21/21 4/28/21 7/22/21 10/21/21 1/20/22 4/28/22 7/27/22 11/14/22 2/14/23 5/23/23 8/10/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: Maart 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 9,811 - 21,814 153,706 139,220 142,947 136,298
Net Cash position 1 4,703 - 3,386 - - - - -
Leverage (Debt/EBITDA) - 0.612 x - 1.107 x 6.555 x 4.61 x 3.768 x 2.917 x
Free Cash Flow 1 -675 -3,211 -3,572 -5,212 2,565 15,765 13,943 17,481
ROE (net income / shareholders' equity) 16.1% 11.7% 10.3% 9.16% 3.52% 3.45% 5.12% 7.54%
ROA (Net income/ Total Assets) 8.16% 5.62% 4.49% 3.78% 1.28% 1.5% 1.95% 3.1%
Assets 1 110,911 133,181 164,922 171,516 362,192 632,803 476,723 454,481
Book Value Per Share 2 50.80 55.90 64.20 70.50 149.0 161.0 168.0 182.0
Cash Flow per Share 2 9.690 10.80 9.690 9.840 15.50 21.40 19.20 44.80
Capex 1 12,221 16,042 15,169 16,978 15,960 21,612 18,628 17,112
Capex / Sales 22.16% 25.19% 21.35% 20.75% 14.28% 14.9% 11.23% 8.77%
Announcement Date 4/25/19 5/14/20 4/28/21 4/28/22 5/23/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Biocon Limited

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
306.4 INR
Average target price
279.1 INR
Spread / Average Target
-8.91%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOCON LIMITED Stock Biocon Limited
+22.73% 4.39B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BIOCON Stock
  4. Financials Biocon Limited